Docosahexaenoic acid (DHA) (22 : 6n-3) is a polyunsaturated fatty acid that is an essential constituent of membranes, particularly of the nervous system. Infants acquire DHA from their mothers, either prenatally via the placenta or postnatally in milk. The present study aimed to test the hypothesis that maternal supplementation during the second and third trimesters of pregnancy enriches maternal and/or fetal DHA status. In a randomised, prospective, double-blind study 100 mothers received either fish-oil capsules containing 400 mg DHA/g (200 mg/d) (n 50), or placebo containing 810 mg oleic acid/g (400 mg/d) (n 50) from 15 weeks gestation until term. Venous blood samples were obtained from mothers at 15, 28 and 40 weeks, and from the umbilical cord at birth. Total fatty acids in plasma and erythrocytes were analysed by GC -MS. There were no significant differences between maternal groups in baseline DHA, as a proportion of total fatty acids (g/100 g total fatty acids) or concentration (nmol/ml), in plasma and erythrocytes. DHA concentrations in plasma at 28 weeks (P=0·02) and erythrocytes at both 28 weeks (P=0·03) and term (P=0·02) were 20 % higher in supplemented mothers than the placebo group. DHA accounted for a higher proportion of total fatty acids in erythrocytes of supplemented mothers at 28 weeks (P=0·003) and term (P=0·01). There were no significant differences between groups in DHA (g/100 g total fatty acids or nmol/l) in cord blood. Maternal DHA status was maximal in mid-trimester and declined to term, at a lower rate in supplemented compared with unsupplemented mothers. Maternal DHA supplementation significantly increases maternal DHA status and limits the last trimester decline in maternal status, aiding preferential transfer of DHA from mother to fetus. Polyunsaturated fatty acid: Docosahexaenoic acid: Mother: Infant * Corresponding author: Professor Lawrence T. Weaver, fax +44 141 201 0837, email lweaver@clinmed.gla.ac.uk Abbreviations: DHA, decosahexaenoic acid; EFA, essential fatty acid; ERY, erythrocyte; PUFA, polyunsaturated fatty acid.
Docosahexaenoic acid (DHA) (22 : 6n-3) is a polyunsaturated fatty acid (PUFA) that is an essential constituent of cell membranes, particularly of the nervous system, where it is found in relatively high concentrations in the brain and retina. In adults, DHA is obtained by endogenous conversion from its parent essential fatty acid (EFA), a-linolenic acid (18 : 3n-3), dependent on an adequate dietary intake of a-linolenic acid and the a-linolenic acid:n-6 EFA ratio, linoleic acid (18 : 2n-6), or preformed in the diet, largely from fish, particularly oily fish. Circulating DHA concentrations correlate with fish intake, even in the west of Scotland where consumption is low and intakes of DHA and oily fish by women of reproductive age are below current dietary recommendations (Berry et al. 2001) .
The developing brain and nervous system have an essential requirement for DHA. Neither the fetal retina nor brain initially synthesise DHA and their capacity to do so is a function of gestational age, making placental transfer crucial (Clandinin, 1999) . The postnatal period is as critical as gestation for the accumulation of long-chain PUFA (Connor, 2000) . In both term and preterm neonates, conversion of a-linolenic acid to DHA occurs, but in limited amounts that may not adequately meet requirements (Carnielli et al. 1996; Salem et al. 1996; Sauerwald et al. 1997) . This is of particular importance as only breast-fed infants receive preformed dietary DHA in the postnatal period.
Maternal PUFA status varies with fish and/or n-3 consumption during pregnancy. Regular consumption of oily fish (Olsen et al. 1991; Sanjurjo et al. 1995) or supplementation with n-3 PUFA (van Houwelingen et al. 1995; Connor et al. 1996) results in an increased circulating maternal DHA status during pregnancy and at term. Following pregnancies in which mothers consume oily fish or n-3 fatty acid supplements, umbilical cord erythrocytes (ERY) and plasma have elevated levels of n-3 PUFA, including DHA, and lower n-6 PUFA status (Sanjurjo et al. 1995; van Houwelingen et al. 1995; Connor et al. 1996) . In addition, the proportion of DHA in cord ERY and plasma correlates not only with maternal blood DHA, but also with maternal dietary n-3 fatty acids (Connor et al. 1996) .
During gestation, accumulation of long-chain PUFA by the fetus elevates the fetal levels of these fatty acids above those in the mother. Generally, relative levels of linoleic acid and a-linolenic acid are higher, while arachidonic acid and DHA are lower in maternal compared with cord plasma triacylglycerols (Berghaus et al. 2000) , plasma phospholipids (Al et al. , 1995a Hoving et al. 1994) and ERY total lipids (Reece et al. 1997 ). Such preferential accumulation or biomagnification (Crawford et al. 1976 ) of long-chain PUFA by the fetus may be the result of maternal long-chain PUFA mobilisation and preferential placental transfer to the fetus Dutta-Roy et al. 1996) .
The contribution of maternal diet to maternal fatty acid status and the subsequent impact of maternal status on that of the fetus is well known. However, previous studies of antenatal maternal supplementation have investigated short periods of supplementation, which often cease prior to delivery, and in determining functional benefits of elevated n-3 fatty acid intake to the neonate have considered the relationship between postnatal diet and development. We are aware of only one study on development in relation to fetal nutrition (Helland et al. 2001) . The effect of maternal supplementation during early pregnancy has therefore not been adequately addressed when considering infant development, although there is evidence that maternal antenatal nutrition influences later visual development (Williams et al. 2001) . The inter-dependence of maternal and fetal nutrition is thus reason to examine the hypothesis that manipulation of maternal diet will enhance both maternal and infant PUFA status, and provide a means by which to optimise infant development.
The aim of the present study, therefore, was to test the hypothesis that antenatal maternal DHA supplementation enriches maternal DHA status and thereby increases the amount available to the fetus and neonate, and influences neonatal visual development. The effect of maternal supplementation on maternal and fetal nutrition, as reflected in maternal ERY and plasma, and (fetal) umbilical cord ERY and plasma, is presented here; the effects on placental tissue, umbilical cord tissue and breast milk, and on infant visual development will be reported elsewhere.
Subjects and methods
A double-blind, placebo-controlled trial was undertaken in which 100 expectant mothers were randomised to receive either fish-oil (n 50) or placebo (n 50) capsules from 15 weeks gestation until term (Table 1) . Fish-oil capsules contained a blended fish oil, Marinol D40 (400 mg DHA/g, 100 mg per capsule); the amount of eicosapentaenoic acid per capsule (approximately 20 mg) was not sufficient to have any pharmacological effect on bleeding time or platelet aggregation (Department of Health, Committee on Medical Aspects of Food Policy, 1994). The placebo consisted of high-oleic-acid sunflower oil containing 810 mg oleic acid/g (18 : 1n-9, 200 mg per capsule) and was devoid of any n-3 fatty acid. Participants took two capsules per d, providing the fish oil-supplemented group with 200 mg DHA/d. The capsules were identical in appearance, taste and odour. The antioxidant used for capsule stability was vitamin E. Both capsule types were donated by RP Scherer Ltd (Swindon, Wilts., UK).
Mothers who were expected to deliver their babies at term and planned to feed their babies on breast and/or formula milk were eligible to participate in the study. Mothers with diabetes, twin pregnancies, pre-eclampsic toxaemia, a past history of abruption or postpartum haemorrhage, allergy to fish products, a thrombophilic tendency or who were receiving drugs that affect thrombocyte function (non-steroidal anti-inflammatory drugs) were excluded. Samples collected at delivery from pregnancies concluded prematurely before 36 weeks, or in which the neonate had an Apgar score . 7 at 10 min, weight below the 3rd centile for gestational age or had visual, medical or developmental problems were not included in the final analysis of results.
Sample size was based on the DHA status of nonpregnant and unsupplemented women within the study population, which is generally low (mean ERY DHA 4·57 (SD 0·82) g/100 g total fatty acids and with little variation (Berry et al. 2001) . Assuming the same range of values at 15 weeks gestation, we hypothesised that supplementation of mothers would increase maternal DHA status by 20 % of baseline (approximately 1 SD). The physiological importance of such an increase could not be determined prospectively, but was measured by postnatal assessment of infant visual development, as reported elsewhere (Malcolm et al. 2003) . The number required per study group to detect a 1 SD difference with a significance level (a) of 0·05 and power (b) of 90 % was 21. Allowing for a 20 % 'drop-out' rate between recruitment, each measurement time and the final measurement at 6 months postpartum, a total of 100 participants (fifty per group) entered the study.
A questionnaire was used to collect information regarding the maternal dietary intake of fish, smoking and exercise patterns, and alcohol consumption. Frequency of dietary fish intake was recorded at 15 weeks gestation, 28 weeks gestation and birth. Fish-intake frequency was classified as never or less than once per week, or once or more per week. Most recent fish consumption prior to obtaining a maternal blood sample at both 15 weeks and 28 weeks gestation was determined to find out if it occurred within the 24 h period prior to sampling. Thus, consumption was classified as either more than 24 h before sampling, or 24 h or less prior to sampling.
At 15 and 28 weeks gestation, participants were given a bottle containing 200 capsules. Compliance in consumption of study capsules was measured by asking participants to return these bottles at the next study time-point (28 weeks gestation or delivery). The number of capsules and time period over which they were consumed were determined, indicating the dosage obtained (Clelend et al. 1992) .
Of the 100 original participants, twenty-nine (n 15 fish-oil group, n 14 placebo group) withdrew from the study between 15 and 28 weeks and seven (n 4 fish oil group, n 3 placebo group) withdrew between 28 weeks and birth. Reasons for withdrawal included nausea gravidarum, poor compliance and loss of contact. It was not possible to obtain blood samples from three mothers at 15 weeks, nine mothers at 28 weeks, three mothers and six neonates at delivery. Two mother -infant pairs in the placebo group were excluded at delivery; one was delivered prematurely, and one was below the 3rd centile for weight for gestational age. Only those with three maternal blood samples (15 weeks, 28 weeks and birth) and an umbilical blood sample were included in the longitudinal analyses.
All pregnancies were singleton and delivered at term. Mothers were representative of the Glasgow population in terms of socio-economic status, as measured using the Carstairs deprivation categories based on residential postcode (Carstairs & Morris, 1990) . The two maternal groups were similar with regard to maternal age, anthropometry, socio-economic status, fish consumption, smoking and alcohol habits. Their infants were of comparable gestational age and anthropometry, and were similar for gender, mode of delivery and feeding practice. Nulliparous women were those for whom the current pregnancy was their first and only; parous women were defined as those with any previously confirmed pregnancy, regardless of outcome or duration.
Antenatal maternal inter-prandial blood samples were collected at enrolment (n 97) and 28 weeks gestation (n 62). Maternal term blood samples (n 59) were obtained within 20 h (mean value) of delivery. Umbilical cord blood samples (n 56) were obtained within 2 h of delivery.
Venous maternal or umbilical cord blood (5 ml) was collected in potassium EDTA (Teklab, Sacriston, Durham, UK). Samples were centrifuged at 550 g (2500 rpm) for 5 min. Plasma was removed and ERY were washed with sterile saline (9 g NaCl/l, 2·5 ml) three times. Both plasma and ERY were stored at 2 708C until analysis.
The fatty acid composition of total lipids in ERY and plasma was analysed. Fatty acids were extracted via a modified Folch extraction (chloroform -methanol (1:1, v/v)) (Folch et al. 1957 ) and derivatised with methanolic hydrochloric acid. An external standard of sixteen available non-esterified fatty acids of known concentration was derivatised concurrently with the samples. The external standard and the samples included an internal standard (15:0 triacylglycerol; Sigma-Aldrich, Poole, Dorset, UK) for calculation of response factors and concentrations. Fatty acid methyl esters were analysed by GC -MS. The GC (Hewlett Packard 5890 Series II; Agilent Technologies, Stockport, Cheshire, UK) was used in split mode (20:1). The carrier gas was He (BOC, Guildford, Surrey, UK), at a flow rate of 1 ml/min. The analytical column was a fused silica capillary column (length 30 m, internal diameter 0·25 mm and film thickness 0·25 mm; BPX70, SGE Europe Ltd, Milton Keynes, UK). GC injector temperature was 2508C and the injection volume was 2 ml. The GC temperature programme was as follows: initial temperature 1208C for 2 min, increasing by 48C per min to 1808C, then by 28C per min to 1948C, followed by 308C per min to 2408C, which was maintained for 1 min. The temperature of the transfer line between the GC and MS was 2808C. The MS (Hewlett Packard 5972) with electron impact ionisation was operated in scanning mode. Fatty acid methyl esters were quantified in both relative and absolute terms: results were expressed as g/100 g total fatty acids based on peak area, and as concentrations (nmol/ml). Relative values were obtained for nineteen individual fatty acids; the concentrations of three fatty acids (22 : 5n-6, 24 : 0 and 24 : 1) could not be determined due to the lack of their non-esterified fatty acid standards and their exclusion from the external standard. In addition, the n-6 and n-3 PUFA classes were each summed (total n-6 and total n-3 fatty acids respectively) and expressed relative to each other (n-6:n-3 fatty acids). The low values for 22 : 5n-6 (docosapentaenoic acid) precluded the use of the DHA:docosapentaenoic acid ratio.
Because the data were not normally distributed, statistical analyses were performed using non-parametric tests. Differences between groups were tested using Mann -Whitney two-sample rank tests, with a chosen significance level of P, 0·05. The longitudinal changes in maternal status and the differences between mother and fetus were not symmetrically distributed and were therefore assessed by one-sample Sign tests at a significance level of P, 0·01. All statistical analyses were performed using Minitab for Windows version 10.51 software (1995; Minitab Inc., State College, PA, USA).
Approval for the study was obtained from both Glasgow University Ethics Committee and Yorkhill Research Ethics Committee, and it was performed with the informed consent of the mothers.
Results
There were no significant differences between supplemented and placebo groups in terms of the number of parous women (x 2 1·478, P. 0·2), or in the frequency of maternal fish consumption at 15 weeks, 28 weeks or delivery (all P. 0·2).
The maternal DHA status of parous women did not differ from that of nulliparous women during gestation or at birth. Cord plasma DHA did, however, differ between the groups: DHA accounted for a higher proportion of total fatty acids (median value 3·6 v. 2·8 g/100 g total fatty acids, P=0·02), and was of a higher concentration (median value 701 v. 350 nmol/ml, P=0·01), in cord plasma obtained from nulliparous women. There were no differences in DHA status of ERY or plasma samples between those whose last previous pregnancy was , 1 year before the current pregnancy, and those whose last previous pregnancy was . 1 year before.
Consumption of fish once or more per week was associated with a higher proportion of DHA in both maternal ERY (median value 3·1 v. 2·4 g/100 g total fatty acids, P=0·003) and plasma (median value 1·8 v. 1·6 g/100 g total fatty acids, P=0·02) at 15 weeks. DHA concentration was not significantly higher at 15 weeks in those who consumed fish once or more per week. Moreover, weekly fish consumption was not associated with higher DHA status after supplementation began, at either 28 weeks or birth.
Fish intake in the 24 h prior to sampling was associated with a higher DHA status, expressed as both a proportion of total fatty acids (median value 1·9 v. 1·6 g/100 g total fatty acids, P=0·004) and as a concentration (median value 154 v. 122 nmol/ml, P=0·005) in maternal plasma at 15 weeks gestation. However, this effect was not observed at 28 weeks, following the commencement of supplementation.
There were no significant differences between fish oilsupplemented and placebo groups in baseline PUFA status at 15 weeks (Table 2 ). In both groups, there was an increase in the concentration and proportion of DHA in maternal ERY and plasma between 15 and 28 weeks, followed by a decrease between 28 weeks and term (Figs 1 and 2). However, at 28 weeks, the concentration of DHA was 22 % higher in plasma (P=0·02) and 13 % higher in ERY (P=0·02) in the fish-oil compared with the placebo group (Table 3) . Arachidonic acid (20 : 4n-6) accounted for a significantly (P=0·02) lower proportion of fatty acids in ERY of fish oil-group mothers at 28 weeks (Table 3 ). In maternal plasma at 28 weeks, the concentration of eicosapentaenoic acid (20 : 5n-3) was significantly (P=0·04) higher in the fish-oil group (Table 3) . These were the only incidences in which the amount of either arachidonic acid or eicosapentaenoic acid was significantly different between treatment groups. At term, ERY DHA concentration remained 42 % higher (P=0·02) in the fish oil-supplemented group. DHA also accounted for a higher proportion of total fatty acids in ERY of fish oil-supplemented mothers at 28 weeks (P=0·003) ( Table 3 ) and at term (P=0·01) ( Table  4 ). Total n-3 fatty acids were elevated, with a concomitant lower n-6:n-3 fatty acid ratio, in the fish-oil group at 28 weeks (Table 3 ) and at birth (Table 4 ) in both maternal ERY and plasma, for both relative and absolute measurements (all P, 0·05). Thus, fish-oil supplementation enhanced the overall maternal DHA and n-3 fatty acid status (Tables 3 and 4 ).
There were no significant differences between supplemented and placebo groups in DHA as a proportion of total fatty acids or concentration in cord blood (Table 5) . In both groups, DHA (proportion of total fatty acids and concentration) was higher in cord than maternal ERY and plasma at birth (Figs 1 and 2) . The relative and absolute amounts of DHA in cord plasma and ERY were most similar to the maximal maternal DHA observed at 28 weeks (Figs 1 and 2) .
Discussion
Fetal and neonatal DHA status are dependent on maternal DHA status. Maternal supplies of DHA are transferred to the fetus via the placenta, and to the neonate via breast milk. Babies who are inadequately supplied with DHA either in utero or postnatally accumulate lower amounts in blood and tissue (Jamieson et al. 1999) , and may be at a disadvantage with regard to neurodevelopment.
In the present study, expectant mothers were supplied with preformed DHA at a dose (200 mg/d) comparable with current dietary recommendations (Department of Health, Committee on Medical Aspects of Food Policy, 1994) and previously shown to be effective in lactating women (Makrides et al. 1996; Helland et al. 1998; Fidler et al. 2000) , to determine its effects on the nutritional status of both mother and fetus.
A differential elevation of circulating DHA and total n-3 fatty acids, with concomitant lowering of the n-6:n-3 fatty acid ratio, was observed in mothers receiving fish-oil compared with placebo supplements. The enrichment of maternal n-3 PUFA status has been noted previously in mothers with a habitually higher amount of fish in their diet throughout pregnancy (Olsen et al. 1991; Sanjurjo et al. 1995) and in mothers supplemented during the last trimester of pregnancy (van Houwelingen et al. 1995; Connor et al. 1996) .
In all measures of circulating DHA status (relative and absolute levels in both ERY and plasma), the same pattern for DHA was noted: an increase in maternal status between 15 and 28 weeks, followed by a decline between 28 weeks and birth, and a subsequently higher cord than maternal DHA status (Figs 1 and 2) . Differences were noted in the magnitude of these changes and in the materno -fetal difference between the groups. The fish-oil group exhibited either an enhanced maternal DHA status, a less pronounced decline in maternal status during the last trimester, and/or a less compromised maternal status relative to fetal status.
Fluctuations in maternal DHA and other PUFA during pregnancy are well reported (Otto et al. 1997) . In particular, the elevation of DHA and long-chain PUFA in the early and mid trimesters (Al et al. 1995a; Ashby et al. 1997; Otto et al. 2001) and subsequent decrease in the last trimester (Al et al. 1995b ) accord with the longitudinal maternal changes observed in both supplemented and placebo groups. The early increase in maternal DHA probably indicates mobilisation of maternal stores to facilitate preferential transfer to and accumulation by the fetus (Al et al. 1995a) , inevitably causing an elevation of fetal relative to maternal DHA pool. The larger maternal increase noted in the fish-oil group of the current study may be attributable to both a greater circulating pool and a larger store in adipose tissue from which to mobilise DHA. The subsequent decline observed between 28 weeks and birth indicates that elevated maternal levels cannot be sustained and that accretion by the fetus probably occurs at the expense of maternal status. Maternal fish-oil supplementation, however, reduces the inevitable last trimester decline in maternal DHA status, and attenuates the difference between maternal and fetal status. It is therefore suggested that while maternal DHA supplementation may not increase fetal ERY status per se, the increase in the overall maternal ERY status during pregnancy may make available to the fetus a greater reservoir from which DHA can be supplied. The relative and absolute amounts of DHA in cord ERY and plasma were consistently higher than in the corresponding maternal sample at birth. Moreover, the materno -fetal difference was generally characterised by lower EFA and higher long-chain PUFA, including arachidonic acid, in cord than maternal blood samples. These findings are in agreement with other comparisons of maternal and fetal fatty acids (Crawford et al. 1989; Al et al. 1990 Al et al. , 1995a van der Schouw et al. 1991; Hoving et al. 1994; Otto et al. 1997; Reece et al. 1997; Berghaus et al. 2000) .
It is perhaps surprising that no differences were observed between groups in the circulating fatty acids of umbilical cord blood, as other studies have reported variations in cord plasma and ERY in relation to maternal diet (Reddy et al. 1994; Al et al. 1995c; Sanjurjo et al. 1995; van Houwelingen et al. 1995; Connor et al. 1996) . However, habitually high intakes of marine foods in the maternal diet are not consistently associated with elevated n-3 PUFA in cord blood (Hornstra et al. 1992 ), suggesting that other factors may be involved when the maternal-tofetal supply is adequate over long periods.
We reported the fatty acid composition of total lipids and therefore do not distinguish between the various lipid fractions of triacylglycerols, phospholipids and cholesteryl esters. Previous studies also differ in the lipid fraction(s) analysed, which may account for some of the differences reported in the literature. Analysis of total lipids determines overall fatty acid status, but does not identify class specific changes or differences. It is therefore possible that the analysis of total lipids in the present study obscured changes during pregnancy, differences between supplemented and placebo groups and/or differences between mother and fetus, which may have been more evident on analysis of distinct lipid fractions. The relative and absolute measurements of fatty acid status are reported here, as together they provide more useful information when considering maternal -fetal transfer of fatty acids Matorras et al. 1994) .
Conservation of the differences between mother and fetus (in both the current and previous studies) suggests a physiological requirement by the fetus to accrue greater amounts of and to attain a higher status of DHA and long-chain PUFA, relative to the mother. Moreover, the requirement appears specific for preformed long-chain PUFA as the fetus accumulates relatively less EFA compared with the mother. Indeed, the lack of difference in cord blood samples between the supplemented and placebo groups suggests that the differential EFA and long-chain PUFA status of mother and infant is a natural physiological process during pregnancy. That manipulation of the maternal diet and DHA status did not influence fetal DHA status is further evidence that DHA accretion by the fetus is a necessity and may be largely pre-determined. Moreover, there may be a threshold level (relative or absolute) that the fetus must attain, which could explain the current and previous (Otto et al. 1997 ) observations that the materno -fetal difference is greater when maternal Fig. 1 . Docosahexaenoic acid (DHA) measured as g/100 g total fatty acids in erythrocytes and plasma in the fish oil-supplemented and placebo groups. Values are medians in maternal blood at 15 and 28 weeks gestation and at birth, and in cord blood. For details of subjects, supplements and procedures, see Table 1 and p. 136. -S -, Fish-oil group erythrocytes (15 weeks n 47, 28 weeks n 30, birth n 29, cord n 27); --B--, placebo group erythrocytes (15 weeks n 49, 28 weeks n 33, birth n 28, cord n 29); -K-, Fish-oil group plasma (15 weeks n 48, 28 weeks n 30, birth n 30, cord n 27); --X--, placebo group plasma (15 weeks n 49, 28 weeks n 33, birth n 28, cord n 29). Fig. 2 . Docosahexaenoic acid (DHA) measured as a concentration in erythrocytes and plasma in the fish oil-supplemented and placebo groups. Values are medians in maternal blood at 15 and 28 weeks gestation and at birth, and in cord blood. For details of subjects, supplements and procedures, see Table 1 and p. 136. -S -, Fish-oil group erythrocytes (15 weeks n 47, 28 weeks n 30, birth n 29, cord n 27); --B--, placebo group erythrocytes (15 weeks n 49, 28 weeks n 33, birth n 28, cord n 29); -K-, fish-oil group plasma (15 weeks n 48, 28 weeks n 30, birth n 30, cord n 27); ---X---, placebo group plasma (15 weeks n 49, 28 weeks n 33, birth n 28, cord n 29). status is low. Fetal requirements appear to be met at the expense of maternal status, which becomes relatively depleted by term. Maternal DHA supplementation apparently limits the extent to which maternal status is compromised by fetal accretion. This may have implications for maternal and fetal status in subsequent pregnancies ).
In conclusion, DHA supplementation of pregnant women enhances maternal plasma and ERY status (proportion of total fatty acids and concentration) and limits the last trimester decline in maternal DHA status. Maternal supplementation may not directly increase fetal DHA status. The biomagnification (Crawford et al. 1976) of DHA from mother to fetus appears to be physiologically pre-determined. The gradient between mother and fetus may, however, be enhanced on the maternal side by fatty acid supplementation, thereby aiding transfer of DHA from mother to fetus.
